These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1281145)

  • 21. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases.
    Wirth MP; Frohmüller HG
    Eur Urol; 1992; 22(1):27-32. PubMed ID: 1385142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seasonal variation of prostatic acid phosphate and prostate-specific antigen in patients without prostatic malignancy.
    Simşek U; Kutlu S; Yavaşçaouğlu I; Oktay B; Ozyurt M
    Eur Urol; 1992; 21 Suppl 1():111-4. PubMed ID: 1385129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor markers in prostate cancer.
    Cooper EH; Robinson MR; Whelan P; Ferro MA
    Cancer; 1992 Jul; 70(1 Suppl):225-9. PubMed ID: 1376192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer.
    van Dalen A; Helmhout DH; van Caubergh RD
    Int J Biol Markers; 1988; 3(2):123-6. PubMed ID: 2468722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1-42 days after transurethral resection of the prostate and orchidectomy.
    Price A; Attwood SE; Grant JB; Gray TA; Moore KT
    Clin Chem; 1991 Jun; 37(6):859-63. PubMed ID: 1710953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate tumour markers as an aid in the staging of prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Liewendahl K; Stenman UH; Alfthan OS
    Br J Urol; 1990 Mar; 65(3):264-7. PubMed ID: 1692497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
    Maier U; Simak R
    Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
    Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M
    Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.
    Han M; Piantadosi S; Zahurak ML; Sokoll LJ; Chan DW; Epstein JI; Walsh PC; Partin AW
    Urology; 2001 Apr; 57(4):707-11. PubMed ID: 11306387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
    Mortarelli EA
    Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
    Kontturi M
    Acta Oncol; 1991; 30(2):169-70. PubMed ID: 1709356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA].
    Gotoh A; Mizuno Y; Takenaka A; Gohji K; Ogawa T; Arakawa S; Kamidono S; Harada K; Nagata H; Hirooka K
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):467-72. PubMed ID: 1712873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.
    Siddall JK; Cooper EH; Newling DW; Robinson MR; Whelan P
    Eur Urol; 1986; 12(2):123-30. PubMed ID: 2420600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostatic specific antigen (PA) in mass screening for prostate cancer].
    Ito K; Ohtake N; Hatori M; Mashimo T; Jimbo S; Tomaru Y; Makino T; Yajima H; Imai K; Yamanaka H
    Hinyokika Kiyo; 1992 Nov; 38(11):1225-9. PubMed ID: 1283053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
    Kraljić I; Kovacić K; Tarle M
    Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.